NR (Nicotinamide Riboside)
NR (Nicotinamide Riboside) scored 6.1 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Exogenous Metabolite.
NR is an oral NAD+ precursor that reliably raises blood NAD+ 40-142% in human studies, but functional outcomes remain mixed: Conze 2019 showed dose-dependent NAD+ elevation, while Dollerup 2018 found no insulin-sensitivity improvement.
What is NR (Nicotinamide Riboside)?
NR, short for nicotinamide riboside, is an oral vitamin B3 derivative used to raise NAD+, a coenzyme your cells need for mitochondrial energy metabolism, DNA repair signaling, and sirtuin activity. The core claim is real but narrow: oral NR raises NAD+ biomarkers in humans. Trammell 2016 established human oral bioavailability, and Conze 2019 found dose-dependent whole-blood NAD+ increases after 100, 300, and 1,000 mg/day.
The controversy is what happens after NAD+ rises. NR enters the NRK1 and NRK2 pathway, becomes NMN, and then contributes to NAD+ pools. That does not guarantee better insulin sensitivity, stronger mitochondria, sharper cognition, or longer life. Dollerup 2018 found no insulin-sensitivity improvement in obese men despite high-dose NR. Elhassan 2019 found muscle NAD+ metabolome changes without functional mitochondrial improvement. Damgaard 2023 summarized the state bluntly: published human NR trials show few clinically relevant effects so far, even though biomarker elevation is consistent.
That makes NR a classic BioHarmony split-score intervention. The supplement does the biochemical thing it says it does, and its safety/regulatory profile is cleaner than most longevity compounds. The clinical payoff is still selective. Parkinson's disease, peripheral artery disease, COPD inflammation, and chronic kidney disease pilots are more interesting than healthy-adult "anti-aging" use. The 2025 update strengthens both sides of the verdict: more evidence confirms NAD+ elevation, while newer reviews such as Prokopidis 2025 temper muscle and function claims.
Terminology
- NAD+: Nicotinamide adenine dinucleotide, the universal redox coenzyme required for mitochondrial energy metabolism, DNA repair signaling, and sirtuin activity.
- NR: Nicotinamide riboside, the vitamin B3 form evaluated in this report.
- NRK1: Nicotinamide riboside kinase 1, an enzyme that phosphorylates NR to NMN in many tissues.
- NRK2: Nicotinamide riboside kinase 2, a muscle-enriched and stress-responsive enzyme that also converts NR to NMN.
- NMN: Nicotinamide mononucleotide, the immediate precursor that can be converted to NAD+ by NMNAT enzymes.
- NAM: Nicotinamide, another vitamin B3 form that feeds the salvage pathway through NAMPT.
- NAMPT: Nicotinamide phosphoribosyltransferase, the rate-limiting enzyme in the classic NAD+ salvage pathway.
- PARP: Poly(ADP-ribose) polymerase, a DNA-repair enzyme family that consumes NAD+.
- Sirtuins: NAD+-dependent enzymes involved in metabolic stress response, chromatin regulation, and mitochondrial signaling.
- Niagen: ChromaDex's branded nicotinamide riboside chloride ingredient used in many major NR trials.
- Basis: Elysium Health's combination of NR plus pterostilbene, studied in Dellinger 2017.
- Pterostilbene: A methylated resveratrol analog included in some NR combination products.
- GRAS: Generally Recognized As Safe, a United States food-use safety pathway. FDA's GRN 635 response applies to specified NR chloride uses.
- NDI: New Dietary Ingredient notification, the United States dietary-supplement pathway for novel supplement ingredients.
- PAD: Peripheral artery disease, a vascular disease where walking limitation was tested in the NICE NR trial.
- MRS: Magnetic resonance spectroscopy, an imaging-adjacent method used to measure tissue metabolites such as brain NAD+.
How do you take NR (Nicotinamide Riboside)?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 3 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral capsule (Tru Niagen standard) | Niagen nicotinamide riboside chloride capsule | 250-1,000 mg/day | 300-1,000 mg/day |
| Oral capsule (generic NR chloride) | Nicotinamide riboside chloride capsule from non-Niagen or licensed suppliers | 300-600 mg/day | 250-1,000 mg/day |
| Combined formulation (NR + pterostilbene) | Elysium Health Basis style formula | 250 mg NR + 50 mg pterostilbene daily | 1-2 capsules daily |
Protocols
Standard maintenance Clinical
- Dose
- 250-300 mg/day oral
- Frequency
- Daily, preferably AM, with or without food
- Duration
- Indefinite if used
Label-style Tru Niagen protocol. Best fit for adults who want a low-friction NAD+ precursor after free lifestyle levers are covered.
Clinical high-dose NAD+ repletion Clinical
- Dose
- 1,000 mg/day oral
- Frequency
- Daily, usually split or AM dosing
- Duration
- 6 weeks to 6 months in clinical studies
Used in Martens 2018, Elhassan 2019, NADPARK, and NICE PAD style protocols. Clinical supervision is more appropriate in disease populations.
High-dose Parkinson's safety protocol Clinical
- Dose
- 1,500 mg twice daily
- Frequency
- Daily
- Duration
- 4 weeks in NR-SAFE
Berven 2023 tested 3,000 mg/day in Parkinson's disease for safety, not consumer longevity. Use only with medical oversight.
Basis combination Clinical
- Dose
- 250 mg NR + 50 mg pterostilbene daily
- Frequency
- Daily
- Duration
- Indefinite if tolerated
Dellinger 2017 found sustained NAD+ increases with this combination; the pterostilbene component makes it distinct from NR-only protocols.
Post-exercise NAD+ recovery Anecdotal
- Dose
- 300-500 mg after training
- Frequency
- Training days
- Duration
- As needed
Community protocol based on PARP and NAD+ turnover after stress. No dedicated RCT shows better recovery than standard daily dosing.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
What are the benefits of NR (Nicotinamide Riboside)?
Upside contribution: 1.26
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.1 | 0.525 | |
| Breadth | 15% | 2.3 | 0.345 | |
| Evidence | 25% | 2.6 | 0.650 | |
| Speed | 10% | 3.0 | 0.300 | |
| Durability | 10% | 1.4 | 0.140 | |
| Bioindividuality | 15% | 2.0 | 0.300 | |
| Total | 2.260 |
Upside Rationale
Nicotinamide riboside moves its surrogate every time and the actual outcome rarely, and that gap is the core efficacy story for NR. Conze 2019 shows the dependable part: whole-blood NAD+ rose 22%, 51%, and 142% at 100, 300, and 1,000 mg/day over 8 weeks. But that NAD+ rise is a surrogate, not a clinical win. Martens 2018 saw only directional vascular signals in a small sample, Dollerup 2018 found no insulin-sensitivity gain at 2,000 mg/day over 12 weeks, and Elhassan 2019 lifted the aged-muscle NAD+ metabolome without improving mitochondrial bioenergetics. For most healthy users, nicotinamide riboside delivers a confident lab change and a modest-to-absent felt change.
Nicotinamide riboside touches many pathways on paper, but its demonstrated human breadth is far narrower than that pathway map. NAD+ sits upstream of energy metabolism, PARP repair, sirtuin signaling, inflammatory tone, and the mitochondrial stress response, so NR looks broad mechanistically. In practice the wins are thin and disease-leaning: small cardiovascular-aging signals plus the peripheral-artery-disease walking distance reported in McDermott 2024. Healthy-adult metabolism, muscle function, cognition, sleep, mood, body composition, skin, and performance stay weak or unsupported. Wu 2025 is the cautionary pattern for nicotinamide riboside: NAD+ rose 2.6 to 3.1 fold in long-COVID patients, yet between-group cognition, fatigue, sleep, anxiety, and depression did not improve. The broad anti-aging halo around NR is a hypothesis the clinical record has mostly not paid out.
Nicotinamide riboside has more human trials than most oral longevity supplements, which is the good news, but the body of work mostly documents a surrogate that misses clinical endpoints. That is why evidence quality reads as solid-but-mixed rather than strong, the has-data-that-mostly-fails pattern. Damgaard 2023 reviewed 25 human NR papers and concluded clinically relevant effects remain limited, and Prokopidis 2025 found current NMN/NR evidence does not support preserving muscle mass or function in older adults. There is no Cochrane review, USPSTF, NICE, or major medical-society recommendation for nicotinamide riboside, and ChromaDex or Niagen funding recurs throughout the literature. So the data on NR exist and are consistent on the biomarker while consistently underdelivering on outcomes, which caps confidence rather than raising it.
Nicotinamide riboside acts fast biochemically and slowly or never on how you feel. The onset story for NR is genuinely quick at the surrogate level: Nanga 2024 found 900 mg raised cerebral NAD+ about 17% just four hours after a single dose in healthy volunteers, and Airhart 2017 showed early blood NAD+ metabolome shifts after oral dosing. Steady-state blood NAD+ generally appears within one to two weeks. Functional timelines, where they exist at all, run much longer: vascular endpoints used six weeks, metabolic trials used twelve, and disease protocols ran a month or more. Because the felt outcome is usually small or absent, the practical speed of nicotinamide riboside is best framed as fast-to-biomarker and indefinite-to-benefit, and most healthy users should expect no obvious same-day effect.
Nicotinamide riboside works only while you keep taking it, with nothing in the human record suggesting a lasting reset. NR behaves like a substrate you feed in, not a retraining signal that holds. When NR stops, blood and tissue NAD+ biology should drift back toward whatever the user's age, diet, illness, and activity state dictate. No human trial shows a durable epigenetic, mitochondrial, vascular, or neurological change that persists after cessation of nicotinamide riboside, and the pharmacokinetic pattern reinforces that sustained oral precursor use is required for sustained systemic and cerebral NAD+ elevation. This is the cleanest part of the read: even the reliable biomarker effect of nicotinamide riboside is rented, not owned, so durability stays low regardless of how dependable the short-term NAD+ rise looks.
Nicotinamide riboside looks more relevant when a larger NAD+ stressor or disease context is present, but even those responder groups carry mixed outcome data. Older adults, Parkinson's disease, peripheral artery disease, COPD inflammation, chronic-kidney-disease oxidative stress, and possibly long-COVID are the more plausible responders to NR than already-healthy young adults. The ceiling on that hope shows up clearly: Orr 2024 raised blood NAD+ 2.6 fold in mild cognitive impairment without improving cognition, and Berven 2023 supports supervised high-dose Parkinson's exploration rather than broad consumer use. The realistic bioindividuality profile for nicotinamide riboside is disease-leaning, age-leaning, and biomarker-driven, with little actionable consumer testing yet for genetic responders or baseline NAD+ deficiency.
What are the risks & downsides of NR (Nicotinamide Riboside)?
Downside contribution: 0.42 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 1.4 | 0.420 | |
| Side effects | 15% | 1.3 | 0.195 | |
| Cost | 5% | 3.0 | 0.150 | |
| Effort | 5% | 1.2 | 0.060 | |
| Opportunity | 5% | 2.5 | 0.125 | |
| Dependency | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.350 | |||
| Harm subtotal × 1.4 | 1.421 | |||
| Opportunity subtotal × 1.0 | 0.335 | |||
| Combined downside | 1.756 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.416 |
Downside Rationale
Nicotinamide riboside has a comparatively clean safety record for a chronic oral supplement, so the real downside is paying for a surrogate that may never become a felt outcome, not a claim that NR is dangerous. EFSA 2020 found NR chloride safe under specified adult use conditions, and FDA's GRN 635 response covers food-use safety as a vitamin B3 source. The watch-items for nicotinamide riboside are forward-looking rather than demonstrated harms: a 2024 preclinical mouse signal raised class-theoretical questions about NAD+ precursors and cancer or brain-metastasis biology, and pregnancy and lactation data remain thin. None of that is a human safety penalty for NR today. FDA's 2020 warning letter confirms nicotinamide riboside is not an approved disease treatment.
Nicotinamide riboside side effects are usually mild and gastrointestinal, which keeps this risk low. Published NR trials report occasional nausea, GI discomfort, headache, and fatigue, with flushing uncommon compared with niacin. Conze 2019 reported no flushing and no significant adverse-event difference between nicotinamide riboside and placebo across 100 to 1,000 mg/day, and Dellinger 2017 found sustained NAD+ elevation with NR plus pterostilbene without major tolerability issues, though that combination cannot be read as pure NR. High-dose use may raise monitoring questions around homocysteine and methyl metabolites. For typical 250 to 500 mg/day users, the side-effect burden of nicotinamide riboside is low-probability and usually reversible by stopping or reducing the dose.
Nicotinamide riboside carries a real and recurring financial cost, and that is its most practical downside. Tru Niagen commonly runs about 40 to 50 dollars per month at 300 mg/day and 70 to 100 dollars per month at 600 mg/day, and a 1,000 mg/day clinical-style protocol costs more. That is not extreme next to peptides or devices, but it is expensive for a supplement most healthy adults never feel, especially given that the benefit of NR is a surrogate rather than a guaranteed outcome. The ChromaDex and Niagen supply chain supports quality control yet also limits true generic price collapse. A budget-constrained user can buy a year of creatine, glycine, magnesium, and taurine for similar or lower cost, with stronger functional data for many goals than nicotinamide riboside offers.
Nicotinamide riboside is easy to execute, so time and effort barely register as a downside. Most NR protocols are one to four capsules daily, usually in the morning, with or without food. There is no required cycling, injection, refrigeration, device setup, fasting window, or behavioral skill. The only added complexity is dose selection: 250 to 300 mg/day for conservative maintenance, 500 to 1,000 mg/day for clinical-style experimentation, and 3,000 mg/day only in clinician-supervised research-like contexts. The one real friction for nicotinamide riboside is adherence: a supplement with no obvious subjective effect is easy to forget or quietly discontinue, which makes a defined tracking plan and a stop rule more important for NR than for interventions you can actually feel working.
Nicotinamide riboside can crowd out higher-return basics for users who have not already covered them, so its opportunity cost is moderate. Exercise increases endogenous NAD+ salvage through NAMPT, and sleep, protein adequacy, metabolic health, and circadian consistency all support energy metabolism without a monthly supplement bill. For many readers, creatine, magnesium, and glycine are better first purchases with stronger functional data than nicotinamide riboside. NR makes more sense once those foundations are handled, or when a clinician-guided disease-population rationale exists. It stacks cleanly enough, but nicotinamide riboside should rarely be a user's first NAD+ intervention or their first supplement dollar.
Nicotinamide riboside shows no evidence of dependency, craving, withdrawal, receptor downregulation, or tolerance in the addiction sense, so this risk is minimal. Stopping NR simply removes the extra NAD+ precursor input and lets biomarkers drift back toward baseline. That pattern is closer to stopping a vitamin or creatine than stopping a psychoactive drug, and no published nicotinamide riboside trial or safety review has identified a withdrawal syndrome. Some users may psychologically prefer to keep buying nicotinamide riboside because they have committed to a longevity protocol and paid for it, but that is habit and sunk-cost expectation rather than physiological dependence. There is nothing about NR that should make stopping difficult on a biological level.
Nicotinamide riboside is fully reversible in practical terms, which is the floor of risk here. NR does not create permanent tissue changes, surgical alterations, device dependence, or known enduring gene-expression effects after cessation. Trammell 2016 and other pharmacokinetic work show nicotinamide riboside behaves like a nutritional precursor with measurable but non-permanent metabolite shifts. If a user experiences GI discomfort, headache, unusual fatigue, or a lab concern, stopping NR is usually enough to resolve it. The only caveat for nicotinamide riboside is that disease-population use, high-dose Parkinson's protocols, pregnancy or lactation questions, and any active cancer concern should be handled with clinician guidance rather than casual self-experimentation.
Is NR (Nicotinamide Riboside) worth it?
NR (Nicotinamide Riboside) is a 6.1 / 10 fit for people who want a measured NAD+ experiment, especially older adults or those tracking vascular, metabolic, or neurologic markers, because NR reliably raises NAD+ biomarkers, but functional benefits are inconsistent. Conze 2019 gives the strongest anchor, while Dollerup 2018 adds useful context without closing the case. The honest gap is simple: higher NAD+ does not automatically mean better energy, metabolism, cognition, or lifespan. That puts NR (Nicotinamide Riboside) in the tracked-experiment category, not the automatic-staple category. In practice, NR (Nicotinamide Riboside) makes the most sense when you monitor NAD+ metabolites, blood pressure, glucose markers, training capacity, fatigue, or neurologic symptoms and avoid treating NR (Nicotinamide Riboside) like a guaranteed longevity supplement.
✅ Best for: Adults 50+ seeking a regulated NAD+ precursor after covering exercise, sleep, protein, and metabolic basics. People who value Niagen chain-of-custody, GRAS/NDI history, and oral convenience over low cost. Parkinson's disease and peripheral artery disease patients who want to discuss adjunctive NR with clinicians, especially after NADPARK, NR-SAFE, and NICE PAD. Users building a broader mitochondrial stack with creatine, CoQ10, magnesium, glycine, urolithin A, and lifestyle levers. Researchers and careful self-quantifiers who care more about NAD+ biomarkers than immediate subjective effects.
❌ Avoid if: You are price-sensitive, expecting caffeine-like energy, or looking for a proven healthy-adult longevity pill. Skip NR until free NAD+ levers are covered: resistance training, zone 2 cardio, sleep regularity, protein adequacy, and meal timing. Avoid unsupervised high-dose use if pregnant, lactating, actively managing cancer, dealing with severe kidney disease, or changing Parkinson's treatment. Athletes should use only batch-tested products because WADA did not surface NR as prohibited, but supplement contamination remains product-specific. Do not use NR as replacement care for diabetes, PAD, COPD, CKD, long-COVID, cognitive impairment, or Parkinson's disease.
What is NR (Nicotinamide Riboside) best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Longevity / Lifespan: 5.0/10
Score: 5.0/10On longevity, NR (Nicotinamide Riboside) deserves 5.0/10 because Dollerup 2018 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: NAD+ decline is an established aging biology theme, and the NRK pathway is well-characterized, but no human lifespan data exists. That does not make NR (Nicotinamide Riboside) a targeted longevity treatment. The report's best evidence is mostly NAD+ biomarker increase with mixed translation into insulin sensitivity, mitochondria, or symptoms, so the score is directional rather than settled. Track harder biomarkers, frailty markers, and function, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Mitochondrial: 5.5/10
Score: 5.5/10For mitochondrial, NR (Nicotinamide Riboside) lands at 5.5/10 because Dollerup 2018 supports the strongest part of the claim. The existing rationale points to this narrower claim: this verified source confirmed raised skeletal-muscle NAD+ metabolome in older men but found no functional mitochondrial bioenergetic improvement. Biochemistry is stronger than. That does not make NR (Nicotinamide Riboside) a targeted mitochondrial treatment. The report's best evidence is mostly NAD+ biomarker increase with mixed translation into insulin sensitivity, mitochondria, or symptoms, so the score is directional rather than settled. Track training capacity, fatigue, and repeatable output, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Neuroprotection: 5.0/10
Score: 5.0/10NR (Nicotinamide Riboside)'s 5.0/10 neuroprotection score starts with Conze 2019, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: NADPARK (this verified source) showed promising Parkinson's signals, and this verified source confirmed acute cerebral NAD+ increase in healthy volunteers. That does not make NR (Nicotinamide Riboside) a targeted neuroprotection treatment. The report's best evidence is mostly NAD+ biomarker increase with mixed translation into insulin sensitivity, mitochondria, or symptoms, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Cardiovascular: 5.0/10
Score: 5.0/10NR (Nicotinamide Riboside) earns 5.0/10 for cardiovascular because Conze 2019 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: this verified source found directional blood-pressure and arterial-stiffness signals in middle-aged and older adults at 1,000 mg/day, and this verified source improved. That does not make NR (Nicotinamide Riboside) a targeted cardiovascular treatment. The report's best evidence is mostly NAD+ biomarker increase with mixed translation into insulin sensitivity, mitochondria, or symptoms, so the score is directional rather than settled. Track heart rate, pace, blood pressure, and recovery, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Metabolic Health: 5.0/10
Score: 5.0/10The metabolic-health case for NR (Nicotinamide Riboside) is 5.0/10 because Martens 2018 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: NAD+ increase supports metabolic pathways, but this verified source found no insulin-sensitivity improvement in obese men at 2,000 mg/day for 12 weeks. That does not make NR (Nicotinamide Riboside) a targeted metabolic-health treatment. The report's best evidence is mostly NAD+ biomarker increase with mixed translation into insulin sensitivity, mitochondria, or symptoms, so the score is directional rather than settled. Track fasting glucose, waist, energy, and appetite, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Healthspan: 5.0/10
Score: 5.0/10A 5.0/10 for healthspan fits NR (Nicotinamide Riboside) because Martens 2018 supports direction more than certainty. The existing rationale points to this narrower claim: Multi-system NAD+ support and disease-population signals justify interest, but healthy-adult function remains mixed per this verified source. That does not make NR (Nicotinamide Riboside) a targeted healthspan treatment. The report's best evidence is mostly NAD+ biomarker increase with mixed translation into insulin sensitivity, mitochondria, or symptoms, so the score is directional rather than settled. Track daily function, recovery, labs, and resilience, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Geriatric / Aging Population: 5.0/10
Score: 5.0/10The practical geriatric read on NR (Nicotinamide Riboside) is 5.0/10 because Conze 2019 anchors the strongest signal. The existing rationale points to this narrower claim: Older adults have larger NAD+ decline, but this verified source did not support NR or NMN for preserving muscle mass or function. That does not make NR (Nicotinamide Riboside) a targeted geriatric treatment. The report's best evidence is mostly NAD+ biomarker increase with mixed translation into insulin sensitivity, mitochondria, or symptoms, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
| Use Case | Score | Summary |
|---|---|---|
| ○ Energy / Fatigue | 4.5 | NAD+ is essential for cellular energy metabolism, but most healthy adults report no obvious subjective energy effect despite biochemical elevation. |
| ○ Nerve Regeneration | 3.5 | NAD+ supports neuronal health and NADPARK suggests neuroprotective potential, but direct human nerve-regeneration evidence for NR remains limited. |
| ○ Endurance / Cardio | 3.5 | McDermott 2024 improved 6-minute walk in PAD, but broader endurance evidence remains limited and disease-specific. |
| ○ Anti-Inflammatory | 3.5 | Elhassan 2019, Norheim 2024, and Ahmadi 2025 support inflammatory-marker interest, but clinical outcome translation remains early. |
| ○ Blood Sugar / Glycemic Control | 3.0 | Dollerup 2018 was explicitly null for insulin sensitivity in obese men at 2,000 mg/day over 12 weeks, so blood-sugar support remains weak despite NAD+ pathway relevance. |
| ○ Cognition / Focus | 3.0 | Wu 2025 found NAD+ rose 2.6- to 3.1-fold in long-COVID, but cognition, fatigue, sleep, anxiety, and depression did not significantly improve versus placebo. |
| ○ Recovery / Repair | 3.0 | NAD+ supports PARP-mediated DNA repair; human recovery-repair endpoints remain indirect and not independently confirmed by dedicated NR RCTs. |
| ○ Cellular Senescence | 3.0 | NAD+ supports DNA repair and senescence-linked pathways, but direct human cellular-senescence outcomes remain indirect. |
Frequently Asked Questions
What is nicotinamide riboside and how does it work?
Nicotinamide riboside is a vitamin B3 derivative that raises NAD+, a coenzyme needed for energy metabolism, DNA repair, and sirtuin signaling. Trammell 2016 confirmed oral bioavailability in humans, while Conze 2019 showed dose-dependent blood NAD+ increases. NR enters cells, is phosphorylated by NRK1 or NRK2 to NMN, then becomes NAD+. That pathway is why NR is the most clinically studied oral NAD+ precursor.
How is NR different from NMN, NAM, and niacin?
All four compounds can feed NAD+ biology, but they enter through different pathways. NR uses NRK1 and NRK2, NMN must be handled through extracellular or intracellular conversion routes, nicotinamide uses NAMPT in the salvage pathway, and niacin uses the Preiss-Handler pathway and can flush. NR's main advantage is regulatory and clinical history: FDA GRN 635 covers specified food uses, and human dosing studies are deeper than for most other NAD+ precursors.
Is NR still legal while NMN has regulatory uncertainty?
Yes, NR has cleaner United States supplement standing than NMN. FDA's GRAS response for nicotinamide riboside chloride says the agency had no questions for specified food uses, and NR has New Dietary Ingredient history. That is ingredient safety and supplement-market support, not a disease-treatment approval. FDA also issued a 2020 ChromaDex warning letter over COVID-19 disease claims, so therapeutic marketing remains restricted.
Does oral NR actually raise NAD+ in humans?
Yes, oral NR reliably raises NAD+ biomarkers in humans. Conze 2019 found whole-blood NAD+ increases of 22%, 51%, and 142% after 100, 300, and 1,000 mg/day for eight weeks. Airhart 2017 and Martens 2018 also showed blood NAD+ elevation. Tissue translation is more mixed: muscle and brain data exist, but functional improvement does not automatically follow in healthy adults overall.
Should I take 250 mg, 500 mg, or 1,000 mg of NR?
For general use, 250-300 mg/day is the conservative starting point because it matches common Tru Niagen dosing. Clinical trials often use 1,000 mg/day, and Berven 2023 tested 3,000 mg/day for four weeks in Parkinson's disease. Higher doses raise NAD+ more, but they have not consistently produced bigger functional benefits in healthy adults. Cost, goals, and medical context matter more than chasing the maximum tolerated dose.
Does NR improve blood pressure, insulin sensitivity, or clinical outcomes?
NR's functional-outcome record is mixed and clearly weaker than its biomarker record. Martens 2018 found directional blood-pressure and arterial-stiffness signals, but the trial was small. Dollerup 2018 found no insulin-sensitivity improvement in obese men at 2,000 mg/day. Elhassan 2019 raised muscle NAD+ metabolites without improving mitochondrial bioenergetics. The newer positive clinical signal is PAD walking distance in McDermott 2024, which needs larger replication.
Is Tru Niagen worth the premium over generic NR?
Tru Niagen is the evidence-traceable default, not automatically the best value for every user. Most major NR trials used Niagen or ChromaDex-supplied material, which supports identity and chain-of-custody confidence. Generic NR chloride may be pharmacologically equivalent if purity is verified, but oversight varies. Because NR is expensive and often subjectively quiet, third-party testing, batch transparency, and realistic expectations matter more than small label-dose differences.
Is NR safe long-term and does it stack with other longevity supplements?
NR appears well tolerated in published human trials, but long-term disease-prevention claims are not proven. Dellinger 2017 found sustained NAD+ increases with NR plus pterostilbene, and EFSA 2020 found NR chloride safe under specified conditions. NR stacks mechanistically with exercise, protein adequacy, creatine, glycine, magnesium, and mitochondrial compounds. The main cautions are pregnancy, active cancer biology questions, severe disease states, and supplement contamination risk for athletes.
What could change NR (Nicotinamide Riboside)'s score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| NADPARK Phase 3 confirms clinically meaningful Parkinson's benefit | Efficacy 2.5 to 3.5; Evidence 3.0 to 3.8 | 6.9 / 10 👍 Worth trying |
| Large independent RCT shows functional benefit in healthy older adults | Efficacy 2.5 to 3.2; Bioindividuality 2.0 to 3.0 | 6.6 / 10 👍 Worth trying |
| Five-year safety surveillance stays clean across high-dose and disease-population use | Evidence 3.0 to 3.5 | 6.3 / 10 👍 Worth trying |
| Multiple null RCTs continue accumulating in healthy adults | Efficacy 2.5 to 2.0 | 6.0 / 10 👍 Worth trying |
| ChromaDex patent pressure eases and verified generic price drops 60% | Cost 3.0 to 2.0 | 6.1 / 10 👍 Worth trying |
| NICE PAD Phase 3 replicates walking-distance benefit | Efficacy 2.5 to 3.2; Breadth 2.8 to 3.3 | 6.6 / 10 👍 Worth trying |
Key Evidence Sources
- Trammell SAJ et al. 2016 - Nicotinamide riboside is uniquely and orally bioavailable in mice and humans, Nature Communications. Corrected v0.x PMID; first human oral bioavailability study with dose-dependent NAD+ metabolome elevation.
- Airhart SE et al. 2017 - Open-label pharmacokinetic study of NR in healthy volunteers, PLOS One. Healthy-volunteer PK and whole-blood NAD+ response across escalating NR dosing.
- Dellinger RW et al. 2017 - Repeat dose NR and pterostilbene increases NAD+ safely and sustainably, npj Aging and Mechanisms of Disease. Combination-formula trial supporting sustained NAD+ increase and tolerability.
- Martens CR et al. 2018 - Chronic NR supplementation elevates NAD+ in healthy middle-aged and older adults, Nature Communications. n=24 crossover RCT; NAD+ elevation with directional vascular-aging signals.
- Dollerup OL et al. 2018 - NR in obese men: safety, insulin sensitivity, and lipid mobilization, American Journal of Clinical Nutrition. n=40; 2,000 mg/day for 12 weeks did not improve insulin sensitivity.
- Conze DB et al. 2019 - Safety and metabolism of long-term NIAGEN administration, Scientific Reports. n=140; 100, 300, and 1,000 mg/day raised whole-blood NAD+ 22%, 51%, and 142%.
- Elhassan YS et al. 2019 - NR augments aged human skeletal muscle NAD+ metabolome, Cell Reports. n=12 crossover; muscle NAD+ metabolome increased, but mitochondrial bioenergetics did not improve.
- EFSA NDA Panel 2020 - Safety of nicotinamide riboside chloride as a novel food, EFSA Journal. Regulatory safety assessment for NR chloride under specified adult and pregnancy/lactation intake conditions.
- Brakedal B et al. 2022 - NADPARK randomized phase I NR trial in Parkinson's disease, Cell Metabolism. n=30; NR increased brain NAD measures and produced early Parkinson's disease signals requiring larger trials.
- Damgaard MV, Treebak JT 2023 - What is really known about NR supplementation in humans, Science Advances. Critical review of 25 published human NR papers; few clinically relevant effects overall.
- Berven H et al. 2023 - NR-SAFE high-dose NR safety trial in Parkinson's disease, Nature Communications. n=20; 3,000 mg/day for 4 weeks was tolerated in Parkinson's disease with methyl-pool monitoring.
- Orr ME et al. 2024 - NR in older adults with mild cognitive impairment, GeroScience. n=20; blood NAD+ rose 2.6-fold, but cognition did not improve.
- McDermott MM et al. 2024 - NICE randomized clinical trial of NR for peripheral artery disease, Nature Communications. n=90; NR improved 6-minute walk distance by 17.6 m versus placebo under prespecified criterion.
- Norheim KL et al. 2024 - NR and airway inflammation in COPD, Nature Aging. n=40 COPD patients plus controls; sputum IL-8 decreased and blood NAD+ more than doubled, with small-sample caution.
- Nanga RPR et al. 2024 - Acute NR supplementation increases human cerebral NAD+ levels in vivo, Magnetic Resonance in Medicine. n=10 healthy volunteers; 900 mg NR increased cerebral NAD+ about 17% four hours after dosing.
- Prokopidis K et al. 2025 - NMN and NR for skeletal muscle mass and function, Journal of Cachexia, Sarcopenia and Muscle. 10 RCTs overall; current evidence did not support NMN or NR for preserving muscle mass/function in older adults.
- Ahmadi A et al. 2025 - NR and coenzyme Q10 on inflammation and oxidative stress in CKD, Clinical Journal of the American Society of Nephrology. n=25 crossover pilot; NR altered metabolism and immune-response gene expression with oxidative-stress-marker changes.
- Wu CY et al. 2025 - NR on NAD+ levels, cognition, and symptom recovery in long-COVID, EClinicalMedicine. n=58; NAD+ rose 2.6- to 3.1-fold, but cognition, fatigue, sleep, anxiety, and depression were not significantly better than placebo.
- FDA 2020 - Warning letter to ChromaDex over Tru Niagen COVID-19 claims. Authority gap signal: NR has supplement ingredient standing, not disease-treatment authorization.
What does the evidence say about NR (Nicotinamide Riboside)?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Trammell 2016, Conze 2019, Martens 2018, Dollerup 2018, Elhassan 2019, Brakedal 2022, Berven 2023, McDermott 2024, Prokopidis 2025, Wu 2025
Pre-RCT-Era Pharmacology and Use
Confidence: Medium
Citations: Goldberger 1914, Elvehjem 1937, Bieganowski 2004, Niagen launch 2013
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for NR (Nicotinamide Riboside)
The three evidence lenses converge on one narrow point: NAD+ and vitamin B3 biology matter. They diverge on intervention specificity. Traditional and historical evidence support preventing B3 inadequacy and understanding NAD+ as essential metabolism, while modern trials show NR capsules reliably raise NAD+ biomarkers but do not consistently improve healthy-adult function. The honest synthesis is to treat NR as a regulated NAD+ repletion tool with disease-population promise, not as proof that more NAD+ automatically means better performance, cognition, or longevity.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Truhealth Nad Metabolism Baseline (pre-protocol)
- hs-CRP During | Expected Down
- ALT During | Expected Stable
- AST During | Expected Stable
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Drive During | Expected Up | Secondary
- Sleep During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Morning Energy Scale 1-5 | During | Expected Up
- Flushing Scale 1-5 | During | Expected Watch
- Sleep Disruption Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Persistent insomnia or agitation
- New unexplained flushing
Other interventions for Longevity
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.260 − 0.416 = 0.844
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.844 / 4.00) × 5 = 6.1 / 10
